Novartis (NVS) Stock Price, News & Analysis

Company Overview

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Key Stats

• Today's Range: $98.12 to $99.24
• 50-Day Range: $96.77 to $105.77
• 52-Week Range: $92.35 to $120.92
• Volume: 1.59 million shs
• Average Volume: 1.13 million shs
• Market Capitalization: $200.65 billion
• P/E Ratio: 11.40
• Dividend Yield: 2.48%
• Price Target: $123.38
• Consensus Rating: Reduce

Novartis Stock Analysis - MarketRank™

Novartis scored higher than 75% of companies evaluated by MarketBeat, and ranked 421st out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Reduce

Consensus Rating

Novartis has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no buy ratings, 6 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Novartis has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 9.45%

Earnings Growth

Earnings for Novartis are expected to grow by 9.45% in the coming year, from $7.62 to $8.34 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Novartis is 11.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 110.89.

Price to Earnings Ratio vs. Sector

The P/E ratio of Novartis is 11.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 86.83.

Price to Earnings Growth Ratio

Novartis has a PEG Ratio of 1.44. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Novartis has a P/B Ratio of 4.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.21% of the float of Novartis has been sold short.

Short Interest Ratio / Days to Cover

Novartis has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novartis has recently decreased by 3.80%, indicating that investor sentiment is improving.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Novartis pays a meaningful dividend of 2.44%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Novartis does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Novartis is 28.22%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Novartis will have a dividend payout ratio of 29.14% next year. This indicates that Novartis will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.21% of the float of Novartis has been sold short.

Short Interest Ratio / Days to Cover

Novartis has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novartis has recently decreased by 3.80%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.35

News Sentiment

Novartis has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Novartis this week, compared to 12 articles on an average week.

Search Interest

11 people have searched for NVS on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.

MarketBeat Follows

Only 11 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is a decrease of -21% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Novartis insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.01% of the stock of Novartis is held by insiders.

Percentage Held by Institutions

Only 13.12% of the stock of Novartis is held by institutions.

NVS Stock Analysis - Frequently Asked Questions

How have NVS shares performed this year?

Novartis' stock was trading at $97.31 at the beginning of 2025. Since then, NVS shares have increased by 0.9% and is now trading at $98.1670.
View the best growth stocks for 2025 here.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) announced its quarterly earnings results on Tuesday, October, 29th. The company reported $2.06 earnings per share for the quarter, beating analysts' consensus estimates of $1.94 by $0.12. The business had revenue of $12.82 billion for the quarter, compared to analyst estimates of $12.62 billion. Novartis had a trailing twelve-month return on equity of 34.80% and a net margin of 35.96%.

Does Novartis have any subsidiaries?

Novartis subsidiaries include these companies: Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and others.

Who are Novartis' major shareholders?

Top institutional investors of Novartis include Janney Montgomery Scott LLC (0.01%), Godsey & Gibb Inc. (0.01%), Douglas Lane & Associates LLC (0.01%) and Boston Common Asset Management LLC (0.01%).

How do I buy shares of Novartis?

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include BlackRock (BLK), Broadcom (AVGO), UnitedHealth Group (UNH), ServiceNow (NOW), Humana (HUM), TotalEnergies (TTE) and American Water Works (AWK).

Company Calendar

• Last Earnings: 10/29/2024
• Today: 1/23/2025
• Next Earnings (Estimated): 1/31/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:NVS
• CUSIP: N/A
• CIK: 1114448
• Web: www.novartis.com
• Phone: (161) 324-1111
• Fax: 41-61-324-7826
• Employees: 76,057
• Year Founded: 1996

Price Target and Rating

• Average Stock Price Target: $123.38
• High Stock Price Target: $130.00
• Low Stock Price Target: $120.00
• Potential Upside/Downside: +25.7%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $8.61
• Trailing P/E Ratio: 11.40
• Forward P/E Ratio: 12.88
• P/E Growth: 1.35
• Net Income: $14.85 billion
• Net Margins: 35.96%
• Pretax Margin: 26.01%
• Return on Equity: 34.80%
• Return on Assets: 15.13%

Debt

• Debt-to-Equity Ratio: 0.55
• Current Ratio: 1.11
• Quick Ratio: 0.90

Sales & Book Value

• Annual Sales: $45.44 billion
• Price / Sales: 4.42
• Cash Flow: $11.18 per share
• Price / Cash Flow: 8.78
• Book Value: $22.87 per share
• Price / Book: 4.29

Miscellaneous

• Outstanding Shares: 2,044,000,000
• Free Float: 2,043,796,000
• Market Cap: $200.65 billion
• Optionable: Optionable
• Beta: 0.57